期刊文献+

门诊骨质疏松患者的用药分析 被引量:1

下载PDF
导出
摘要 目的探究骨质疏松患者的用药情况。方法回顾性分析我院自2010年2月至2012年1月接收诊治的300例骨质疏松患者的门诊处方,统计分析其性别、年龄、用药情况等。结果所有300例患者中男性患者74例,占24.7%,女性患者226例,占75.3%,根据对患者用药情况的统计分析发现维生素D及衍生物用量最大、而2种药物的联合用药方式最为常用。结论骨质疏松疾病的主要人群以中老年级绝经后妇女为主,联合用是目前临床应用最为广泛的治疗手段,双膦酸盐对骨质疏松的预防、治疗有积极作用。
作者 钟裕权
机构地区 梅州市人民医院
出处 《中国医药指南》 2013年第31期77-78,共2页 Guide of China Medicine
  • 相关文献

参考文献4

二级参考文献36

  • 1石元俊.原发性骨质疏松症的研究进展[J].中国临床新医学,1999,12(3):209-217. 被引量:2
  • 2Linday R,Burge RT,Strauss DM.One year outcomes and costs following a vertebral fracture[J].Osteoporosis Int,2004,1 (16):78-85.
  • 3Fink H,Ensrud K,Nelson D,et al.Disability after clinical fracture in postmenopausal women with low bone density:the fracture intervention trial (FIT)[J].Osteoporosis Int,2003,14 (1):69-76.
  • 4Mazanec D.Osteoporosis screening:time to take responsibility[J].Arch Intern Med,2004,164(10):1047-1048.
  • 5Recker R,GallaghcrR,Mac Cosbe P.Effect of dosing frequency on bisphosphonates medication adherence in a large longitudinal cohort of women[J].Mayo Clin Proc,2005,80 (7):856-861.
  • 6Cramer J,Gold D,Silverman S,et al.A systomatic review of persistence and compliance with bispbosphonates for osteoporosis[J].Osteoporosis Int,2007,18 (8):1023-1031.
  • 7Black D,Delmas P,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.
  • 8Papaioannou A,Kennedy CC,Ioannidis G,et al.The impact of incident fractures on health-related quality of life:5 years of data from the Canadian Multicentre Osteoporosis Study.Osteoporos Int,2009,20:703-714.
  • 9Bouxsein ML,Kaufman J,Tosi L,et al.Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture.J Am Acad Orthop Surg,2004,12:385-395.
  • 10Kanis JA,on behalf of the World Health Organization Scientific Group.Assessment of osteoporosis at the primary health-care level.Technical Report,UK:WHO Collaborating Centre,University of Sheffield,2008.

共引文献87

同被引文献14

  • 1张俊,葛宁,黄晓丽,张新军.骨质疏松症的药物治疗评价[J].中国实用内科杂志:临床前沿版,2006,26(2):313-315. 被引量:25
  • 2孟迅吾,朱汉民,刘建立,罗邦尧,谢海宝,张光健,李佛保,李梅.阿仑膦酸钠治疗绝经后骨质疏松症的疗效与耐受性[J].基础医学与临床,2007,27(2):174-177. 被引量:27
  • 3Blouin S, Gallois Y, Moreau M F, et al. Disuse and orchidectomy have additional effects on bone loss in the agedmale rat[ J]. Osteoporos Int, 2007,18 ( 1 ) :85-92.
  • 4Gullberg B, Johnell O, Kanis JA. World-wide projections for hipfracture. Osteoporos Int, 1997,7:407-413.
  • 5JiangHX, Majumdar SR, Dick DA, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patientswith hip fractures. J BoneMiner Res, 2005,20:494-500.
  • 6Reid DM,Hosking D, Kendler D, et al. A Comparison of the effect of alendronate and Risedronate on bone mineral density in postmenopausal with osteoporosis 24 -month results from FACTS- International[ J]. Int J Clin Pratt, 2008, 62(4) : 575.
  • 7Chapurlat RD, Palermo L, Ratneay P, et al. Women who lose bone density during risk of fracture with alendronate among fracture intervent trial [ J ]. Osteoporos Int, 2005, 16 (7) : 842-848.
  • 8Lyles KW, Coin Emetic CS, Magaziner et al. Zoledronie acid and clinical fractures after hip fracture [ J ]. N Engl J Med, 2007, 357: 1799-1809.
  • 9Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis [ J ]. Am JMed, 2009, 122 : S14.
  • 10Lehrer S, Montazem A, Ramanathan L, et al. Bisphosphonate-induced osteoneerosis of the jaws, bone markers, and a hypothesized candidate zene [ J q. J Oral Maxillofac Surz JT. 2009.67 ( 1 ) : 159-161.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部